Background {#Sec1}
==========

Worldwide, 35 million people were living with HIV at the end of 2013 \[[@CR1]\]. Sub-Saharan Africa remains the most severely affected region, accounting for 71% of the people living with HIV \[[@CR1]\]. In Uganda at least 130,000 HIV new infections occur every year \[[@CR2]\]. In 2013, an estimated 1.6 million Ugandans were living with HIV, and an estimated 63,000 people died of AIDS-related illnesses \[[@CR3]\] including HIV related cancers. In the African setting Kaposi sarcoma remains the commonest AIDS related malignancy and lymphoma has also increased due to HIV epidemic \[[@CR4]\].

HIV increases the risk of lymphoma, especially non-Hodgkin's lymphoma (NHL) \[[@CR5]\] resulting in it being categorized as an AIDS defining illness \[[@CR6]\]. In Uganda the frequency of lymphomas particularly NHL, the more frequent type has increased since the beginning of the HIV/AIDS pandemic in the early 1980s \[[@CR7]\]. The incidence of NHL among HIV infected individuals is 7.3 cases per 100,000, being 6.7-fold higher compared to HIV uninfected persons \[[@CR9]\]. The Kampala Cancer Registry reports the incidence of NHL in Kampala is increasing by 6.7% annually in men and 11% annually in women since the beginning of the HIV pandemic.

A study done in Uganda showed that all HIV-positive Ugandans with NHL not receiving HAART die within 1 year of NHL diagnosis \[[@CR9]\]. NHL and other AIDS related lymphomas are typically more advanced at presentation \[[@CR5]\]. The advanced stage III and stage IV lymphoma disease have been used in the international prognostic index (IPI) tool to predict survival in aggressive lymphoma in which are associated with poor survival rates. It is therefore paramount to have an early diagnosis and treatment of lymphoma before it presents with advanced stage III and IV disease. These diseases have nonspecific symptoms; commonly presenting with lymphadenopathy and constitutional symptoms of fever, weight loss and night sweats, and can also affect extra-nodal sites, giving rise to atypical presentations \[[@CR9]\]. These symptoms mimic other HIV opportunistic infections like tuberculosis (TB) \[[@CR10]\]. TB is the leading cause of morbidity and mortality in HIV with extra pulmonary TB (EPTB) on a rise in sub-Saharan Africa. TB affects any part of the body resulting in a nonspecific clinical presentation depending on the organ of the body affected including fevers, night sweats, weight loss and lymphadenopathy.

Lymphoma diagnosis is challenging even for pathologists in developed nations without hematopathological specialization \[[@CR9]\]. The gold standard for the diagnosis of lymphoma is biopsy and histology. These are invasive and limited by the need for skill and unavailability of pathology centers in many health centers. As a result diagnosis is missed and commonly HIV patients with lymphadenopathy and constitutional symptoms are usually empirically treated for TB resulting into delayed diagnosis of lymphoma \[[@CR9]\] especially in rural settings. In a south African retrospective study, 18/21 patients with lymphoma had received anti-TB treatment in the preceding 12 months before diagnosis of lymphoma was made \[[@CR9]\]. This study had a small sample size limiting the interpretation of the findings and it did not look at the factors associated with the misdiagnosis. In this study, we aimed to investigate the frequency and factors associated with lymphoma misdiagnosis as TB among a substantial population of HIV positive patients diagnosed with lymphoma attending the Uganda Cancer Institute, Mulago Hospital, Kampala.

Methods {#Sec2}
=======

Design and setting {#Sec3}
------------------

A retrospective cohort chart review was carried out between February and March 2015 at the Uganda Cancer Institute (UCI) in Kampala located in Mulago Hospital complex. UCI is a national cancer referral center receiving about 3000 new cancer patients annually. Majority of these patients are referred from Mulago National Referral and Teaching Hospital with a histological diagnosis which is then re-assessed at the UCI and biopsy samples reexamined. The Institute receives about 3--4 new patients with lymphoma every month according to local data. Charts of documented HIV infected patients who attended the UCI from January 2004 to November 2014 with a histological diagnosis of lymphoma were reviewed. Patients were allocated into two arms, those with and without a history of TB treatment (Fig. [1](#Fig1){ref-type="fig"}). Patients charts who had a history of TB treatment more than 12 months prior to the diagnosis of lymphoma together with patients charts that had missing data on the history of TB treatment were excluded from the study.Fig. 1Study inclusion criteria. *TB* tuberculosis, *HAL* HIV associated lymphoma

Trained data clerks retrieved patient charts from the records department at UCI and extracted the required information into a standard data form. Blood investigations, (Hemoglobin, lactate dehydrogenase and CD4 cell count) and imaging (abdominal ultrasound and chest x-ray) were extracted. The age, sex, address, level of education, clinical presentation of fevers, night sweats, lymphadenopathy and ascites were captured.

History of TB treatment was recorded within the last 12 months prior to diagnosis of lymphoma, site of TB, duration on anti-TB' treatment before diagnosis of lymphoma and the method of TB diagnosis to capture bacteriological versus empirical diagnosis of TB. Patients with a history of empirical TB treatment with no clinical improvement who later got a histological diagnosis of lymphoma were considered a possible misdiagnosis (Fig. [1](#Fig1){ref-type="fig"}). Type and stage of HIV associated lymphoma were also recorded.

Statistical analysis {#Sec4}
--------------------

Data obtained was checked and entered using EPI-DATA. Analysis was performed using Stata version 13 Software. Frequency of TB misdiagnosis in patients with HIV associated lymphoma was established as a proportion among the total HIV associated lymphoma patients studied. Categorical variables were summarized as percentages and frequencies while continuous variables were summarized as median and interquartile range. To establish factors associated with misdiagnosis of TB in patients with lymphoma, bivariate analysis was performed using a Chi square test statistic for the categorical variables and a Wilcoxon rank-sum (Mann--Whitney) test for the numeric/continuous variables and those with a conservatively set *p* value \<0.2 were analyzed using multivariate regression analysis. Variables with final p values \<0.05 were considered to be associated with a misdiagnosis of HIV associated lymphoma.

Results {#Sec5}
=======

Patient characteristics {#Sec6}
-----------------------

From February to March 2015; 221 clinical charts of HIV- infected patients with lymphoma attending the Uganda Cancer Institute were reviewed of which 38 were excluded because of missing data on TB treatment leaving a total of 183 patient files.

There were 106/183 (57.9%) males; the median age was 35 years (IQR 28--45). Many of these participants had attained primary education 167/183 (91%). 91/183 (49.7%) were married and 19/183 (10.4%) were widowed. Lymphadenopathy was the commonest presentation at 161/183 (91%) with chest pain at 44/183 (24.3%) and dyspnea at 43/183 (23.5%) being the least. The median CD4 cell count was relatively low, 232 cells/μl. Those who had received anti-TB were treated for a median time of 3.5 (1--5.3) months before a histological diagnosis of lymphoma was made due to failure to respond to TB medication (Table [1](#Tab1){ref-type="table"}). Of the 183 patients with lymphoma, NHL accounted for 119/183 (65%) and Hodgkin's lymphoma (HL) was 64/183 (30%). Most patients 142/183 (77.6%) presented with advanced cancer, with mainly stage III and IV lymphoma, 7/183 (3.8%) had stage I lymphoma disease. Only 120 out of 183 (65.4%) patients were on highly active anti-retroviral therapy.Table 1Baseline Characteristics of HIV/lymphoma patientsBaseline characteristicsn%Gender (n = 183) Female7742.1 Male10657.9Marital status (n = 183) Divorced/separated3619.7 Married9149.7 Single3720.2 Widowed1910.4Occupation (n = 183) Casual laborer3921.3 Civil servant3016.4 House wife3318 Peasant4122.4 Trader4021.9Education (n = 183) None168.7 Primary8043.7 Secondary6334.4 Tertiary2413.1Fever (n = 183) No3720.2 Yes14679.8Chest pain (n = 181) No13775.7 Yes4424.3Cough (n = 183) No11663.4 Yes6736.6Drenching night sweats (n = 183) No3619.7 Yes14780.3Loss of appetite (n = 180) No3720.6 Yes14379.4Lymph node swelling (n = 177) No169 Yes16191Dyspnea (n = 183) No14076.5 Yes4323.5Median (IQR)Age (years)35 (28--45)HAART duration (months)18 (5--18)Duration on anti TB (months)3.5 (1--5.3)CD4 count232 (124--387)Body mass index19.5 (17.1--21.6)Hemoglobin10.2 (8.4--12.1)LDH value462 (302--772)*HAART* anti-retroviral therapy, *LDH* lactate dehydrogenase, *IQR* inter quartile range

Sixty patients (32.8%) had history of TB treatment of which 56/183 (30.6%) had received empirical TB treatment while 4/183 (0.02%) had treatment for bacteriologically confirmed TB. Majority of the patients with a history of TB treatment 51/60 (85%) had been treated for EPTB. The 56 patients \[56/183 (30.6%)\], with initial empirical TB treatment did not improve with TB treatment, and were considered to have a possible misdiagnosis (Fig. [1](#Fig1){ref-type="fig"}; Table [2](#Tab2){ref-type="table"}).Table 2Clinical characteristics of HIV associated lymphoma patientsLymphoma type, ART and TB statusn%Documented lymphoma type HL6435 NHL11965 Total183100.0HAART No6334.4 Yes12065.4 Total183100.0Lymphoma stage Stage I73.8 Stage II3418.6 Stage III7138.8 Stage IV7138.8Total183100.0Site of TB EPTB5185.0 PTB915.0 Total60100.0*HAART* anti-retroviral therapy, *TB* tuberculosis, *HL* Hodgkin's lymphoma, *NHL* non Hodgkin's lymphoma, *EPTB* extra pulmonary tuberculosis, *PTB* pulmonary tuberculosis

Comparison of characteristics between possible misdiagnosis and definite diagnosis {#Sec7}
----------------------------------------------------------------------------------

Table [3](#Tab3){ref-type="table"} shows the results of the bivariate analysis in which stage of lymphoma \[OR 4.03 (95% CI 1.49--10.93, p \< 0.006)\], dyspnea \[OR 2.46 (95% CI 1.01--5.97, p \< 0.01)\], fever \[OR 3.62 (95% CI 1.31--10.01, p \< 0.016)\], drenching night sweats \[OR 4.41 (95% CI 1.45--3.37, p \< 0.008)\], chest pain \[OR 3.3 (95% CI 1.46--7.46, p \< 0.004)\], hemoglobin level \[OR 0.88 (95% CI 0.78--0.99, p \< 0.034)\], ART status \[OR 1.88 (95% CI 0.93--3.8, p \< 0.070)\] and loss of appetite \[OR 4.17 (95% CI 1.51--11.52, p \< 0.016)\], were associated with possible lymphoma misdiagnosis as TB.Table 3Comparison of characteristics between possible misdiagnosis and definitive diagnosisCharacteristicsNo misdiagnosis n (%)Misdiagnosis n (%)P-valueFever No32 (86.5)5 (13.5) Yes95 (65.1)51 (34.9)*0.012*Chest pain No107 (78.1)30 (21.9) Yes18 (40.9)26 (59.1)*0.001*Drenching night sweats No32 (88.9)4 (11.1) Yes95 (64.6)52 (35.4)*0.005*Loss of appetite No32 (86.5)5 (13.5) Yes93 (65.0)50 (35.0)*0.012*Dyspnea No104 (74.3)36 (25.7) Yes23 (53.5)20 (46.5)*0.010*HAART status No49 (77.8)14 (22.2) Yes78 (65.0)42 (35.0)*0.075*Stage of lymphoma Stage I and II36 (87.8)5 (12.2) Stage III and IV91 (64.1)51 (35.9)*0.004*Cough No84 (72.4)32 (27.6) Yes43 (64.2)24 (35.2)0.240Lymph node swelling No12 (75.0)4 (25.0) Yes113 (70.9)48 (29.8)0.680Median (IQR)Median (IQR)HAART duration (months) duration (months) duration (months)24 (8--36)12 (4--36)*0.020*CD4 count275 (146--458)172 (96--234)*0.001*Hemoglobin10.5 (9--12.4)9.8 (7.1--11.3)*0.020*LDH value462 (319--721)468 (263--845)0.880No association with Gender, Marital status, Education and Body mass index*HAART* anti-retroviral therapy, *LDH* lactate dehydrogenase, IQR inter quartile range

These variables were further used for multivariate analysis to determine the factors associated with possible misdiagnosis of HIV/lymphoma co infected patients as TB patients. The multivariate analysis shown in Table [4](#Tab4){ref-type="table"} revealed chest pain and stage of lymphoma to be independently associated with possible misdiagnosis of lymphoma aOR 1.46 (95% CI 0.41--5.23, p \< 0.001) and aOR 3.22 (95% CI 1.08--9.63, p \< 0.04) respectively. The CD4 count was excluded at multivariate analysis due to missing data. ART duration was excluded because not every study participant was on HAART.Table 4Multivariate analysis for possible misdiagnosis of HIV associated lymphoma patientsCharacteristicsCrude oddsP-valueAdjusted oddsP-valueChest pain No1.001.00 Yes3.3 (1.46--7.46)*0.004*4.4 (1.89--10.58)*0.001*Stage of lymphoma Stage I and II1.001.00 Stage III and IV4.03 (1.49--10.93)*0.006*3.22 (1.08--9.63)*0.037*Drenching night sweats No1.001.00 Yes4.41 (1.45--3.37)0.0081.44 (0.39--5.24)0.585Loss of appetite No1.001.00 Yes4.17 (1.51--11.52)0.0162.85 (0.76--10.77)0.122 Dyspnea No1.001.00 Yes2.46 (1.01--5.97)0.0101.31 (0.56--3.04)0.535 Highly Active Anti-retroviral Therapy status No1.001.00 Yes1.88 (0.93--3.8)0.0701.82 (0.82--4.09)0.142Fever No1.001.00 Yes3.62 (1.31--10.01)0.0161.46 (0.41--5.23)0.563 Hemoglobin0.88 (0.78--0.99)0.0340.94 (0.82--1.07)0.344

Discussion {#Sec8}
==========

In our study we found three in every ten patients with HIV associated lymphoma attending UCI, had a possible misdiagnosis before a final diagnosis of lymphoma was made. These patients were treated for TB for a median period of 16 weeks prior to correct diagnosis. The WHO 2003 TB treatment guidelines for national programmes suggest empirical TB treatment in HIV infected patients with symptoms of TB, stressing the importance of follow-up investigations and reviews of treatment response after 1 month \[[@CR11]\] to rule out other diseases that mimic TB. If followed as recommended, early review of treatment response offers opportunities for earlier investigation and diagnosis of other diseases especially lymphoma that mimics TB in order to improve survival.

Majority of these patients were treated for EPTB, and therefore stand a high chance to be registered as EPTB treatment failures in national statistics and for this reason, this high frequency of misdiagnosis of lymphoma as TB could be contributing to the low EPTB treatment success rate of 66% reported by the WHO for Uganda \[[@CR11]\].

Our study is the first to explore clinical symptoms and signs that are associated with possible misdiagnosis of TB among lymphoma patients. We found all patients in our retrospective cohort to be symptomatic with more than one constitutional symptom. Chest pain, stage of lymphoma, fever, HAART status, low hemoglobin, dyspnea, drenching night sweats and loss of appetite were the main factors found to be associated with TB misdiagnosis in bivariate analysis. Although many patients presented with lymphadenopathy, it was not found to be associated with misdiagnosis of Lymphoma. The risk of being initiated on empirical anti-TB treatment prior to the diagnosis of lymphoma was 4.4 times in cases where one had chest pain and 3.2 times in cases where one had stage III and IV lymphoma disease as compared to no chest pain and stage I and II lymphoma disease respectively. This indicates that advanced lymphoma (stage III and IV) is symptomatically very similar to TB as chest pain is a common symptom in TB \[[@CR9]\].

Our findings were somewhat different from the South African study with a lower frequency of misdiagnosis 30.6% compared to theirs, 85.7% and shorter length of TB treatment prior to lymphoma diagnosis. These differences may be explained by a smaller sample size in the South African study of (21 patients) or the retrospective nature of the South African study although similar to ours, dealt with patients directly rather than data.

Worryingly our data also showed a low rate of ART (65.4%). Our study did not allow for CD4 count analysis as it was not undertaken in the HIV clinic setting, however, a lymphoma diagnosis gives a patient an HIV WHO stage of IV which necessitates ART initiation. Earlier work in Uganda shows that mortality in those with lymphoma and HIV not on ART is 100%. HIV and cancer specialists should consider strategies that increase communication for patient care, such as the integrated HIV--TB model that has streamlined care for co-infected patients and decreased mortality.

Our retrospective design and tertiary care setting, would have led to an underestimation of the true rate of misdiagnosis as some patients may have died or been lost to follow-up before being referred to the UCI. Data was collected using non-standardized clinical notes extracted from medical charts which potentially lead to recording bias, selection bias and missing data. Despite these limitations, we feel that our findings send an important message to clinicians managing patients empirically treated with TB, especially EPTB to be alert from the beginning to the possibility of an alternative diagnosis of HIV associated lymphoma.

This study showed a co-morbidity rate of lymphoma and TB to be 6.7%, which is consistent with a study by De La Rosa et al. \[[@CR12]\] that showed a co-occurrence of 6%. Therefore, clinicians have to consider an additional as well as alternative diagnosis if the response to either lymphoma or TB treatment is not achieved.

Conclusion {#Sec9}
==========

A high proportion of patients with HIV associated lymphoma attending UCI are possibly misdiagnosed and treated as TB. Chest pain and stage III and IV of lymphoma were associated with a risk of possible misdiagnosis of lymphoma as TB. Clinicians treating HIV patients for TB should have a low threshold for investigating lymphoma.

PB, LN, HD, RPR designed the study; PB, DN extracted and collated data for analysis; PB and SW conducted data analysis; Interpretation of data was conducted by PB, LN, HD, RPR. PB drafted the manuscript that was then revised and finalized by SR, RPR, and LN with contributions from all authors. All authors read and approved the final manuscript.

Acknowledgements {#FPar1}
================

I am grateful to Prof. Wally Schelch, Dr. Musoke Charles, Dr. Richard Ssekitoleko and Mr. Mubiru Frank (statistician) for support in the building of this project. I am thankful to the staff and researchers of IDI, specifically, Dr. Okware S, Dr. Sekagya C, for their willingness to provide support at all times. Lastly thanks to the people of the Uganda Cancer Institute for allowing me to use their data.

Competing interests {#FPar2}
===================

The authors declare that they have no competing interests.

Availability of data and materials {#FPar3}
==================================

Please contact corresponding author for data requests.

Ethical approval {#FPar4}
================

Consent and assent waiver to review patient's charts and ethical approval of the study was granted by the School of Medicine Research and Ethics committee Makerere University (SOMREC).

Funding {#FPar5}
=======

This study was self-sponsored as part of a master's project.

Support for manuscript writing was provided by Fogarty International Center, National Institutes of Health (Grant \#D43TW009771 "HIV co-infections in Uganda: TB, Cryptococcus, and Viral Hepatitis").

Supported in part (SJR) by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
